Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Currently available somatostatin analogs are not good for Graves' orbitopathy.

Literature DB >> 16794359

Currently available somatostatin analogs are not good for Graves' orbitopathy.

M L Tanda, L Bartalena.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16794359 DOI： 10.1007/BF03344119

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

× No keyword cloud information.

18 in total

Review 1. New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors: R A Ajjan; A P Weetman
Journal: J Endocrinol Invest Date: 2004-03 Impact factor: 4.256

2. New insights on SOM230, a universal somatostatin receptor ligand.

Authors: V Boerlin; J van der Hoek; Ch Beglinger; K W Poon; S Hartmann; C Dutreix; J M Kovarik; Ch Bruns; G Weckbecker; I Lewis; P Schnieper; L J Hofland; S W J Lamberts
Journal: J Endocrinol Invest Date: 2003 Impact factor: 4.256

3. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease.

Authors: Daniela Pasquali; Antonio Notaro; Giulio Bonavolonta'; Patrizia Vassallo; Antonio Bellastella; Antonio Agostino Sinisi
Journal: J Clin Endocrinol Metab Date: 2002-11 Impact factor: 5.958

4. Psychosocial morbidity of Graves' orbitopathy.

Authors: G J Kahaly; F Petrak; J Hardt; S Pitz; U T Egle
Journal: Clin Endocrinol (Oxf) Date: 2005-10 Impact factor: 3.478

Review 5. Management of Graves' ophthalmopathy: reality and perspectives.

Authors: L Bartalena; A Pinchera; C Marcocci
Journal: Endocr Rev Date: 2000-04 Impact factor: 19.871

6. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy.

Authors: D Pasquali; P Vassallo; D Esposito; G Bonavolontà; A Bellastella; A A Sinisi
Journal: J Mol Endocrinol Date: 2000-08 Impact factor: 5.098

7. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

Authors: J L Wémeau; P Caron; A Beckers; V Rohmer; J Orgiazzi; F Borson-Chazot; M Nocaudie; P Perimenis; S Bisot-Locard; I Bourdeix; S Dejager
Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958

8. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.

Authors: A Jane Dickinson; Bijay Vaidya; Margaret Miller; Alan Coulthard; Petros Perros; Elizabeth Baister; Christopher D Andrews; Lutz Hesse; Johannes T Heverhagen; Armin E Heufelder; Pat Kendall-Taylor
Journal: J Clin Endocrinol Metab Date: 2004-12 Impact factor: 5.958

Currently available somatostatin analogs are not good for Graves' orbitopathy.

Review 1. New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

2. New insights on SOM230, a universal somatostatin receptor ligand.

3. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease.

4. Psychosocial morbidity of Graves' orbitopathy.

Review 5. Management of Graves' ophthalmopathy: reality and perspectives.

6. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy.

7. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

8. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.

Review 9. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.

Review 10. Effects of Graves' ophthalmopathy on quality of life.

1. Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Review 2. Thyroid eye disease: current and potential medical management.